First-in-world approval of FemBloc delivery system for women seeking permanent birth controlATLANTA, March 13, 2025 (GLOBE NEWSWIRE) -- Femasys Inc.,...
Boston (March 13, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated...
Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood Samples...
SANTA ANA, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage...
SAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the...
Second clinical program entering Phase 2 with data expected 2026BRISBANE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc....
Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute Second Versamune® platform...
Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1 Trial of...
Olympus Will Highlight the Platform at Annual SAGES Meeting CENTER VALLEY, Pa., March 12, 2025 /PRNewswire/ -- Olympus Corp., a...
Astronauts to Support Cutting-Edge Biomedical Investigations, NSF-Funded Physical Science Projects, and More Through the ISS National Lab KENNEDY SPACE CENTER,...
Astronauts to Support Cutting-Edge Biomedical Investigations, NSF-Funded Physical Science Projects, and More Through the ISS National Lab KENNEDY SPACE CENTER,...
LOS ANGELES, March 12, 2025 /PRNewswire/ -- Salt AI, founded by the high-performance computing (HPC) team behind MySpace, today announces its...
LOS ANGELES, March 12, 2025 /PRNewswire/ -- Salt AI, founded by the high-performance computing (HPC) team behind MySpace, today announces its...
Content-Driven Program Brings Together Clinical Trial Stakeholders to Foster Knowledge Sharing and Collaboration in Cancer Research COLUMBIA, Md., March 12,...
Content-Driven Program Brings Together Clinical Trial Stakeholders to Foster Knowledge Sharing and Collaboration in Cancer Research COLUMBIA, Md., March 12,...
Harnessing generative AI to develop targeted therapies for DNA damage response, including hard-to-treat central nervous system malignanciesVANCOUVER, British Columbia, March...
Largest shareholder, CK Life Sciences Int’l., (Holdings) Inc. agrees to conversion of debt into equity, removing all existing debt from...
Encouraging Safety Profile Supports Progression Toward First Dual-Administration of Selective A2A and A2B Antagonists in PatientsDOVER, Del., March 12, 2025...
GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a leading public health...
Late-breaking clinical and first translational data from BOND-003 Cohort C will be presentedIRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) --...